Royalty Pharma's $950 million acquisition of a royalty interest in Amgen’s approved small cell lung cancer drug, Imdelltra, underlines expanding market confidence. Imdelltra employs bispecific T-cell engagement to harness immune responses, validated by FDA accelerated approval and strong commercial uptake. This transaction exemplifies growing investor interest in immuno-oncology assets with substantial market potential in aggressive cancers.